ETON news

Eton Pharmaceuticals announced the ET-900 program, an Investigational New Drug (IND) application for mecasermin in refractory epileptic spasms, leveraging research from Baylor College of Medicine seeking to address the high resistance rates of current epileptic spasms therapies.

Eton Pharmaceuticals and Aquestive Therapeutics announced a U.S. licensing agreement for LIBERVANT buccal film, targeting a U.S. market opportunity exceeding $450 million. The deal is expected to advance Eton's rare disease portfolio and provide a near-term growth opportunity in neurology.

Eton entered an exclusive licensing agreement with Aquestive for LIBERVANT buccal film, targeting a U.S. seizure rescue market exceeding $450 million annually with an anticipated April 2027 commercial launch.

Eton Pharmaceuticals launched its U.S. commercial availability for IMPAVIDO (miltefosine) capsules. This expansion into Eton's rare disease infrastructure simplifies patient access through expanded support programs and a centralized pharmacy distribution network.

Eton Pharmaceuticals licensed the late-stage ASN-001 drug from Auson Pharmaceuticals for treating infantile hemangiomas, projecting significant portfolio revenue growth.

Eton Pharmaceuticals entered into a supply and distribution agreement to gain exclusive U.S. commercialization rights to IMPAVIDO (miltefosine) from Knight Therapeutics, effective September 26, 2026. The acquisition of this FDA-approved orphan drug expands Eton's rare disease portfolio and represent…